|Mr. John H. Tucker||Pres, CEO, CFO & Director||604.05k||N/A||1963|
|Dr. Klaus R. Veitinger M.B.A., M.D., MBA, Ph.D.||Independent Director||37.5k||N/A||1962|
|Ms. Rachael Nokes||Sr. VP of Fin. & Principal Accounting Officer||N/A||N/A||1975|
|Katherine Taudvin||Director of Corp. Devel. & Investor Relations||N/A||N/A||N/A|
|Dr. John Mohr Pharm.D.||Sr. VP of Clinical Devel. & Medical Affairs||N/A||N/A||N/A|
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
scPharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.